ArticleMolecular psychiatry2013
Dopamine receptor D1 and postsynaptic density gene variants associate with opiate abuse and striatal expression levels.
Article in Molecular psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- The influence of dopamine receptor SNPs on substance use disorder in a Jordanian cohort.BMC research notes · 2025Article
- Genetic and Epigenetic Approaches to Opioid Use Disorder.Expert reviews in molecular medicine · 2025Review
- Biochemical Diagnosis in Substance and Non-substance Addiction.Advances in experimental medicine and biology · 2025Review
- Circadian rhythm disruptions associated with opioid use disorder in synaptic proteomes of human dorsolateral prefrontal cortex and nucleus accumbens.Molecular psychiatry · 2023Article
- Heroin delay discounting and impulsivity: Modulation by DRD1 genetic variation.Addiction biology · 2020Article
- Epigenetic Mechanisms of Opioid Addiction.Biological psychiatry · 2020Review
- Regulation and Function of Activity-Dependent Homer in Synaptic Plasticity.Molecular neuropsychiatry · 2019Review
- Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.Frontiers in psychiatry · 2019Review
- Ventral striatal regulation of CREM mediates impulsive action and drug addiction vulnerability.Molecular psychiatry · 2018Article
- Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors.Frontiers in psychiatry · 2018Article
- Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls.Pharmacogenomics · 2018Article
- Article
- Glutamatergic and GABAergic susceptibility loci for heroin and cocaine addiction in subjects of African and European ancestry.Progress in neuro-psychopharmacology & biological psychiatry · 2016Article
- Overlapping dopaminergic pathway genetic susceptibility to heroin and cocaine addictions in African Americans.Annals of human genetics · 2015Article
- Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants.Pharmacogenomics · 2014Article
- Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).Molecular neurobiology · 2014Article
- Genetics of opiate addiction.Current psychiatry reports · 2014Review
- Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric.Journal of behavioral addictions · 2014Review
- A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the μ opioid receptor gene OPRM1 via hnRNPH interactions.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Dopamine and glucose, obesity, and reward deficiency syndrome.Frontiers in psychology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
Abstract
Opioid drugs are highly addictive and their abuse has a strong genetic load. Dopamine-glutamate interactions are hypothesized to be important for regulating neural systems central for addiction vulnerability. Balanced dopamine-glutamate interaction is mediated through several functional associations, including a physical link between discs, large homolog 4 (Drosophila) (DLG4, PSD-95) and dopamine receptor 1 (DRD1) within the postsynaptic density to regulate DRD1 trafficking. To address whether genetic associations with heroin abuse exist in relation to dopamine and glutamate and their potential interactions, we evaluated single-nucleotide polymorphisms of key genes within these systems in three populations of opiate abusers and controls, totaling 489 individuals from Europe and the United States. Despite significant differences in racial makeup of the separate samples, polymorphisms of DRD1 and DLG4 were found to be associated with opiate abuse. In addition, a strong gene-gene interaction between homer 1 homolog (Drosophila) (HOMER1) and DRD1 was predicted to occur in Caucasian subjects. This interaction was further analyzed by evaluating DRD1 genotype in relation to HOMER1b/c protein expression in postmortem tissue from a subset of Caucasian subjects. DRD1 rs265973 genotype correlated with HOMER1b/c levels in the striatum, but not cortex or amygdala; the correlation was inversed in opiate abusers as compared with controls. Cumulatively, these results support the hypothesis that there may be significant, genetically influenced interactions between glutamatergic and dopaminergic pathways in opiate abusers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.